Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine.

IF 1.6 Q4 ONCOLOGY

International Journal of Breast Cancer Pub Date : 2018-01-22 eCollection Date: 2018-01-01 DOI:10.1155/2018/4879406

Fumito Kuranishi, Yuki Imaoka, Yuusuke Sumi, Yoji Uemae, Hiroko Yasuda-Kurihara, Takeshi Ishihara, Tsubasa Miyazaki, Tadao Ohno

{"title":"Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine.","authors":"Fumito Kuranishi, Yuki Imaoka, Yuusuke Sumi, Yoji Uemae, Hiroko Yasuda-Kurihara, Takeshi Ishihara, Tsubasa Miyazaki, Tadao Ohno","doi":"10.1155/2018/4879406","DOIUrl":null,"url":null,"abstract":"Introduction: No effective treatment has been developed for bone-metastatic breast cancer. We found 3 cases with clinical complete response (cCR) of the bone metastasis and longer overall survival of the retrospectively examined cohort treated comprehensively including autologous formalin-fixed tumor vaccine (AFTV).Patients and methods: AFTV was prepared individually for each patient from their own formalin-fixed and paraffin-embedded breast cancer tissues.Results: Three patients maintained cCR status of the bone metastasis for 17 months or more. Rate of cCR for 1 year or more appeared to be 15% (3/20) after comprehensive treatments including AFTV. The median overall survival time (60.0 months) and the 3- to 8-year survival rates after diagnosis of bone metastasis were greater than those of historical control cohorts in Japan (1988-2002) and in the nationwide population-based cohort study of Denmark (1999-2007).Conclusion: Bone-metastatic breast cancer may be curable after comprehensive treatments including AFTV, although larger scale clinical trial is required.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2018-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/4879406","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Breast Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2018/4879406","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Introduction: No effective treatment has been developed for bone-metastatic breast cancer. We found 3 cases with clinical complete response (cCR) of the bone metastasis and longer overall survival of the retrospectively examined cohort treated comprehensively including autologous formalin-fixed tumor vaccine (AFTV).

Patients and methods: AFTV was prepared individually for each patient from their own formalin-fixed and paraffin-embedded breast cancer tissues.

Results: Three patients maintained cCR status of the bone metastasis for 17 months or more. Rate of cCR for 1 year or more appeared to be 15% (3/20) after comprehensive treatments including AFTV. The median overall survival time (60.0 months) and the 3- to 8-year survival rates after diagnosis of bone metastasis were greater than those of historical control cohorts in Japan (1988-2002) and in the nationwide population-based cohort study of Denmark (1999-2007).

Conclusion: Bone-metastatic breast cancer may be curable after comprehensive treatments including AFTV, although larger scale clinical trial is required.

Abstract Image

查看原文本刊更多论文

包括自体福尔马林固定肿瘤疫苗在内的骨转移性乳腺癌综合治疗后1年及以上的临床完全缓解率

骨转移性乳腺癌没有有效的治疗方法。我们发现3例骨转移的临床完全缓解(cCR)和回顾性检查队列综合治疗包括自体福尔马林固定肿瘤疫苗(AFTV)的总生存时间更长。患者和方法:分别从患者自身的福尔马林固定和石蜡包埋的乳腺癌组织中制备AFTV。结果:3例患者骨转移cCR状态维持17个月以上。经包括AFTV在内的综合治疗后1年及以上的cCR率为15%(3/20)。诊断为骨转移后的中位总生存时间(60.0个月)和3- 8年生存率均高于日本(1988-2002)和丹麦(1999-2007)的历史对照队列研究。结论:骨转移性乳腺癌经包括AFTV在内的综合治疗是可以治愈的，但需要更大规模的临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Breast Cancer ONCOLOGY-

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

19 weeks

期刊介绍： International Journal of Breast Cancer is a peer-reviewed, Open Access journal that provides a forum for scientists, clinicians, and health care professionals working in breast cancer research and management. The journal publishes original research articles, review articles, and clinical studies related to molecular pathology, genomics, genetic predisposition, screening and diagnosis, disease markers, drug sensitivity and resistance, as well as novel therapies, with a specific focus on molecular targeted agents and immune therapies.